Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1215
mi
from 02139
Bradenton, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1215
mi
from 02139
Bradenton, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
1233
mi
from 02139
Ft. Lauderdale, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
1233
mi
from 02139
Ft. Lauderdale, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1080
mi
from 02139
Gainesville, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1080
mi
from 02139
Gainesville, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1130
mi
from 02139
Kissimmee, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1130
mi
from 02139
Kissimmee, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1112
mi
from 02139
Leesburg, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1112
mi
from 02139
Leesburg, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1229
mi
from 02139
Oakland Park, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1229
mi
from 02139
Oakland Park, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1110
mi
from 02139
Orlando, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1110
mi
from 02139
Orlando, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
934
mi
from 02139
Atlanta, GA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
934
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
929
mi
from 02139
Decatur, GA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
929
mi
from 02139
Decatur, GA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
846
mi
from 02139
Chicago, IL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
846
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1482
mi
from 02139
Lake Charles, LA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1482
mi
from 02139
Lake Charles, LA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1410
mi
from 02139
Shreveport, LA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1410
mi
from 02139
Shreveport, LA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
389
mi
from 02139
Rockville, MD
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
389
mi
from 02139
Rockville, MD
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1250
mi
from 02139
Flowood, MS
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1250
mi
from 02139
Flowood, MS
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1046
mi
from 02139
Creve Couer, MO
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1046
mi
from 02139
Creve Couer, MO
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1033
mi
from 02139
St. Louis, MO
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1033
mi
from 02139
St. Louis, MO
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
262
mi
from 02139
Marlton, NJ
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
262
mi
from 02139
Marlton, NJ
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
212
mi
from 02139
Neptune, NJ
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
212
mi
from 02139
Neptune, NJ
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
541
mi
from 02139
Canton, OH
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
541
mi
from 02139
Canton, OH
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes' Investigational Study Site
720
mi
from 02139
Mason, OH
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes' Investigational Study Site
720
mi
from 02139
Mason, OH
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1490
mi
from 02139
Oklahoma City, OK
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1490
mi
from 02139
Oklahoma City, OK
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1490
mi
from 02139
Oklahoma City, OK
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1490
mi
from 02139
Oklahoma City, OK
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
268
mi
from 02139
Philadelphia, PA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
818
mi
from 02139
Charleston, SC
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
818
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1125
mi
from 02139
Memphis, TN
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1125
mi
from 02139
Memphis, TN
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
1691
mi
from 02139
Austin, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
1691
mi
from 02139
Austin, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
1691
mi
from 02139
Austin, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
1691
mi
from 02139
Austin, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1541
mi
from 02139
Dallas, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1541
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1541
mi
from 02139
Dallas, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1541
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1556
mi
from 02139
Desoto, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1556
mi
from 02139
Desoto, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1603
mi
from 02139
Houston, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1603
mi
from 02139
Houston, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
1603
mi
from 02139
Houston, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
1603
mi
from 02139
Houston, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
2091
mi
from 02139
Salt Lake City, UT
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
2091
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
2474
mi
from 02139
Bellvue, WA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
2474
mi
from 02139
Bellvue, WA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
2360
mi
from 02139
Richland, WA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
2360
mi
from 02139
Richland, WA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Intergrated Medical and Behavioral Associates
2586
mi
from 02139
Glendale, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Intergrated Medical and Behavioral Associates
2586
mi
from 02139
Glendale, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Excell Research, Inc.
2566
mi
from 02139
Oceanside, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Excell Research, Inc.
2566
mi
from 02139
Oceanside, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
University of California, San Diego
2550
mi
from 02139
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
University of California, San Diego
2550
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Affiliated Research Institute
2573
mi
from 02139
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Affiliated Research Institute
2573
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Schuster Medical Research Institute
2596
mi
from 02139
Sherman Oaks, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Schuster Medical Research Institute
2596
mi
from 02139
Sherman Oaks, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Scientific Clinical Research
1249
mi
from 02139
North Miami, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Scientific Clinical Research
1249
mi
from 02139
North Miami, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Uptown Research Institute, Llc
846
mi
from 02139
Chicago, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Uptown Research Institute, Llc
846
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Alexian Brothers Behavioral Health
870
mi
from 02139
Hoffman Estates, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Alexian Brothers Behavioral Health
870
mi
from 02139
Hoffman Estates, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CBH Health LLC
389
mi
from 02139
Rockville, MD
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CBH Health LLC
389
mi
from 02139
Rockville, MD
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CRI Worldwide, LLC
254
mi
from 02139
Willingboro, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CRI Worldwide, LLC
254
mi
from 02139
Willingboro, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Carolina Clinical Trials, Inc.
816
mi
from 02139
Charleston, SC
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Carolina Clinical Trials, Inc.
816
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Vanderbilt Psychiatric Hospital
941
mi
from 02139
Nashville, TN
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Vanderbilt Psychiatric Hospital
941
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
FutureSearch Clinical Trials LP
1689
mi
from 02139
Austin, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
FutureSearch Clinical Trials LP
1689
mi
from 02139
Austin, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
InSite Clinical Research LLC
1556
mi
from 02139
DeSoto, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
InSite Clinical Research LLC
1556
mi
from 02139
DeSoto, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
4184
mi
from 02139
Arkhangelsk,
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
4184
mi
from 02139
Arkhangelsk,
Click here to add this to my saved trials